A.R. IBRAGIMOVA¹, A.R. BELGOLOVA¹, N.D. SHAIMARDANOVA¹, L.YU. DAVIDYAN², A.YU. BOGDASAROV², R.A. BOGDASAROVA²

 ¹Kazan State Medical University, Kazan

²Ulyanovsk State University, Ulyanovsk

Contact details:

Ibragimova A.R. — PhD (Medicine), Associate Professor of the Department of Obstetrics and Gynecology named after Prof. V.S. Gruzdev

Address: 49 Butlerov St., 420012 Kazan, Russian Federation, tel.: + 7-927-762-19-87, e-mail: ibr_alina@mail.ru

 Endometrioid ovarian cysts are a common manifestation of genital endometriosis affecting women of reproductive age. Comprehensive treatment for endometriosis implies drug therapy (including postoperative treatment) to reduce the risk of endometrioid cyst recurrence, which largely leads to reduced chronic pelvic pain and improved quality of life.

The purpose — to evaluate the impact of the duration of postoperative therapy with dienogest on quality of life, severity of endometriosis symptoms, and side effect profile in patients after surgical treatment of endometrioid ovarian cysts.

Material and methods. The authors surveyed 43 patients who underwent surgery for endometrioid ovarian cysts between 2023 and 2024 using a Google Forms questionnaire. All women were divided into two comparison groups: the first group included 36 women who used dienogest for three months and the second group included 50 patients who took the drug for one year.

Results. The study showed that patients taking dienogest long-term reported fewer complaints of pain and changes in their psychoemotional state, including mood swings, aggression, and irritability. An assessment of additional complaints reported by women during the survey revealed statistically significant differences between the compared groups. A decrease in libido was not observed in any patient who discontinued dienogest, but was reported in more than a third of patients who continued long-term therapy.

Conclusion. Long-term postoperative therapy with dienogest was significantly more effective in improving quality of life compared to a short-term course. The results proved the feasibility of prolonged use of dienogest, considering the favorable safety profile of the drug.

Key words: endometrioid cysts, dienogest, quality of life, EHP-30

REFERENCES

1. Klinicheskiye rekomendatsii «Endometrioz», 2024 [Clinical guidelines «Endometriosis», 2024], available at: http://disuria.ru/_ld/14/1476_kr24N80MZ.pdf (accessed on: 1.03.2026).
2. VOZ [WHO], available at: https://www.who.int/ru/news-room/fact-sheets/detail/endometriosis (accessed on: 21.02.2026).
3. Adamyan L.V., Andreyeva E.N. Endometriosis and its global impact on the woman’s body. Problemy reproduktsii, 2022, vol. 28, no. 1, pp. 54–64 (in Russ.). DOI: 10.17116/repro20222801154
4. Tskhay V.B. Adenomioz. Kontravesii sovremennosti. Boli. Krovotecheniya. Besplodiye [Adenomyosis. Contrabalances of modern times. Pain. Bleeding. Infertility]. Moscow: Redaktsiya zhurnala StatusPresens, 2020. 208 p.
5. Safronova A.S., Buralkina N.A., Burduli A.G., Arakelyan A.S., Chuprynin V.D., Adamyan L.V. Reproductive Potential of Patients with Various Forms of Endometriosis (Literature Review). Problemy reproduktsii, 2021, vol. 27, no. 1, pp. 24–32 (in Russ.).
6. Besplodiye i endometrioz. Versiya i kontraversiya, pod red. V.E. Radzinskogo, M.R. Orazova [Infertility and Endometriosis. Version and Controversy, Ed. by Radzinsky V.E., Orazov M.R.]. Moscow: Redaktsiya zhurnala StatusPresens, 2019. 208 p.
7. Wattanayingcharoenchai R., Rattanasiri S., Charakorn C., Attia J., Thakkinstian A. Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis. BJOG, 2021, vol. 128, rr. 25–35. DOI: 10.1111/1471-0528.16366
8. Thiel P.S., Donders F., Kobylianskii A. et al. The effect of hormonal treatment on ovarian endometriomas: a systematic review and meta-analysis. Minim Invasive Gynecol., 2024, vol. 31 (4), pp. 273–279. DOI: 10.1016/j.jmig.2024.01.002
9. Angioni S., Pontis A., Malune M.E. et al. Is dienogest the best medical treatment for ovarian endometrio-mas? Results of a multicentric case control study. Gynecol. Endocrinol., 2020, vol. 36 (1), pp. 84–86. DOI: 10.1080/09513590.2019.1640674
10. Li R.R., Xi Q., Tao L. et al. A systematic review and Bayesian analysis of the adverse effects of dienogest. BMC Pharmacol. Toxicol, 2024, vol. 25 (1), p. 43. DOI: 10.1186/s40360-024-00767-1
11. Muzii L., Di Tucci C., Galati G. et al. The efficacy of dienogest in reducing disease and pain recurrence after endometriosis surgery: a systematic review and meta-analysis. Reprod. Sci, 2023, vol. 30 (11), pp. 3135–3143. DOI: 10.1007/s43032-023-01266-0
12. Eberle A., Nguyen D.B., Smith J.P. et al. Medical management of ovarian endometriomas: a systematic review and meta-analysis. Obstet. Gynecol, 2024, vol. 143 (1), pp. 53–66. DOI: 10.1097/AOG.0000000000005444
13. Jones G.L., Budds K., Taylor F. et al. 13. A systematic review to determine use of the endometriosis health profiles to measure quality of life outcomes in women with endometriosis. Reprod. Update, 2024, vol. 30 (2), pp. 186–214, available at: https://pubmed.ncbi.nlm.nih.gov/38007607/ DOI: 10.1093/humupd/dmad029
14. Murji A., Biberoglu K., Leng J. et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr. Med. Res. Opin, 2020, vol. 36, pp. 895–907. DOI: 10.1080/03007995.2020.1744120
15. La Torre F., Vannuccini S., Toscano F. Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability. Gynecol. Endocrinol, 2024, vol. 40 (1), pp. 2336121. DOI: 10.1080/09513590.2024.2336121
16. Maiorana A., Maranto M., Restivo V. et al. Evaluation of long-term efficacy and safety of dienogest in patients with chronic cyclic pelvic pain associated with endometriosis. Arch. Gynecol. Obstet, 2024, vol. 309 (2), pp. 589–597. DOI: 10.1007/s00404-023-07271-7
17. Piacenti I., Tius V., Viscardi M.F., Biasioli A., Arcieri M., Restaino S. et al. Dienogest vs. combined oral contraceptive: A systematic review and meta-analysis of efficacy and side effects to inform evidence-based guidelines. Acta Obstet. Gynecol. Scand, 2025, vol. 104 (8), pp. 1424–1432. DOI: 10.1111/aogs.15145